Dr Sandra Black and colleagues from Sunnybrook conduct a 24 week randomized double blind trial to test the efficacy of donepezil in severe AD ( mean MMSE around 7). Findings suggest modest benefit for cognition and global function. Patients had severe AD but were community dwelling and were also naive to the treatment intervention, perhaps this drug provides a 'once only' benefit in AD?
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment